Mobius Therapeutics’ Mitosol Earns Payment Indicator for Reimbursement

Mobius Therapeutics, ophthalmic surgery solutions company based in St. Louis, has announced that the Center for Medicare & Medicaid Services has given the company Outpatient Prospective Payment System Payment Indicator K2 for the reimbursement of Mitosol.

Advertisement

Hospitals and ASCs billing under OPPS will now be allowed payment for the Mitosol Kit for Ophthalmic Use.

Mitosol is designed to deliver antifibrotics during corneal, glaucoma and refractive surgeries.

More Articles on Ophthalmology:

MCRHS Eye Care Welcomes Dr. Elizabeth Garland
AAO Survey Finds US Ophthalmologists Foresee Negative Consequences of Medicare Cuts
Paragon BioTeck Names Dr. Paul Koch US Medical Advisor

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.